MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• MiNK Therapeutics has received a consensus rating of "Hold" from six research firms, with varying recommendations including two sell, two buy, and one strong buy.
• The company's stock has declined 3.8% recently, with a market cap of $63.32 million and a current trading price around $14.00.
• MiNK Therapeutics reported a quarterly earnings per share of (-$1.06), missing consensus estimates and indicating a projected (negative) earnings per share of -$2.75 for the current fiscal year.

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given a consensus rating of "Hold" by the six research firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $37.50.

A number of equities analysts recently weighed in on the stock. William Blair lowered shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. Zacks Research lowered shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, August 18th. Wall Street Zen lowered shares of MiNK Therapeutics to a "strong sell" rating in a report on Saturday, August 23rd. B. Riley upgraded shares of MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. Finally, HC Wainwright upgraded shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective for the company in a report on Friday, August 15th.

MiNK Therapeutics Stock Down 3.8%

Shares of NASDAQ INKT opened at $14.00 on Friday. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00. The firm has a market cap of $63.32 million, a P/E ratio of -4.86 and a beta of 0.33. The company has a 50 day moving average of $14.54 and a 200 day moving average of $11.78.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.51). As a group, equities analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.